Left ventricular systolic function and the pattern of late-gadolinium-enhancement independently and additively predict adverse cardiac events in muscular dystrophy patients

Table 3 Distribution of primary and secondary endpoints

	Total (N = 88)	DMD (N = 20)	BMD(N = 68)	p-value
Mean follow-up duration, months	47 ± 18	47 ± 13	47 ± 19	0.92
Primary endpoint, n (%)	3 (3)	1 (5)	2 (3)	0.54
Secondary endpoint, n (%)	21 (24)	1 (5)	20 (29)	0.034
Hospitalization for HF, n (%)	8 (9)	0 (0)	8 (12)	0.190
Non-/sustained VT, n (%)	14 (16)	1 (5)	13 (19)	0.175

DMD – Duchene muscular dystrophy; BMD – Becker muscular dystrophy. HF – heart failure; VT – ventricular tachycardia. Bold numbers indicate significant p-values/parameters.

ISSN: 1532-429X